Fertility preservation in BRCA-mutated women: when and how?

Autor: J. Raad, Isabelle Cedrin-Durnerin, Marjorie Comtet, Michael Grynberg, Charlotte Sonigo, C. Vinolas
Přispěvatelé: Unité de Biologie Fonctionnelle et Adaptative (BFA (UMR_8251 / U1133)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Jazyk: angličtina
Rok vydání: 2018
Předmět:
HEREDITARY BREAST
Cancer Research
endocrine system diseases
[SDV]Life Sciences [q-bio]
Genes
BRCA2

Genes
BRCA1

Gene mutation
Bioinformatics
0302 clinical medicine
FEMALE FERTILITY
Fertility preservation
Ovarian Reserve
skin and connective tissue diseases
media_common
AMERICAN-SOCIETY
Ovarian Neoplasms
education.field_of_study
030219 obstetrics & reproductive medicine
Fertility Preservation
General Medicine
female genital diseases and pregnancy complications
3. Good health
Oncology
030220 oncology & carcinogenesis
Female
BREAST-CANCER PATIENTS
Risk
Genotype
PREIMPLANTATION GENETIC DIAGNOSIS
media_common.quotation_subject
ADJUVANT TAMOXIFEN
Population
Breast Neoplasms
Fertility
OVARIAN-CANCER
03 medical and health sciences
Ovulation Induction
medicine
Humans
Genetic Testing
education
Ovarian reserve
Preimplantation Diagnosis
Cryopreservation
Pregnancy
INTERNATIONAL CONSENSUS GUIDELINES
business.industry
BRCA mutation
PREMATURE MENOPAUSE
Cancer
medicine.disease
Mutation
business
IN-VITRO FERTILIZATION
Zdroj: Future Oncology
Future Oncology, Future Medicine, 2018, 14 (5), ⟨10.2217/fon-2017-0415⟩
ISSN: 1479-6694
1744-8301
Popis: International audience; BRCA 1 and 2 genes play a critical role in the safeguarding of DNA integrity. It is now well established that BRCA1 and BRCA2-mutated women are at increased risk of breast and ovarian cancers. However, several lines of evidence indicate that this genetic status may also be associated with ovarian dysfunction, in particular a reduced ovarian reserve. Considering the gonadal toxicity of cancer treatments and the recommendation of prophylactic bilateral salpingo-oophorectomy around 40 years, young BRCA mutation carriers are confronted with difficult family planning decisions. Recent development in fertility preservation offers new possibilities for these women, not only before a potential cancer treatment, but also in healthy carriers. If the pregnancy seems to be safe in this population, oocyte vitrification following ovarian stimulation might help BRCA-mutated patients to conceive after cancer treatment or to undergo prenatal genetic diagnosis in order to avoid the risk of transmitting the genetic abnormality to their offspring. The present article aims to extensively discuss the fertility issues related to BRCA gene mutations and the questions raised by the possibility of fertility in this population.
Databáze: OpenAIRE